SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001178913-23-002860
Filing Date
2023-08-14
Accepted
2023-08-14 08:05:56
Documents
28
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 6-K zk2330149.htm   iXBRL 6-K 25361
2 EXHIBIT 99.1 exhibit_99-1.htm   iXBRL EX-99.1 534898
3 EXHIBIT 99.2 exhibit_99-2.htm EX-99.2 152743
4 EXHIBIT 99.3 exhibit_99-3.htm EX-99.3 159194
10 GRAPHIC image00002.jpg GRAPHIC 7975
  Complete submission text file 0001178913-23-002860.txt   2169121

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE cmmb-20230630.xsd EX-101.SCH 19275
6 XBRL CALCULATION FILE cmmb-20230630_cal.xml EX-101.CAL 24395
7 XBRL DEFINITION FILE cmmb-20230630_def.xml EX-101.DEF 39292
8 XBRL LABEL FILE cmmb-20230630_lab.xml EX-101.LAB 204554
9 XBRL PRESENTATION FILE cmmb-20230630_pre.xml EX-101.PRE 82531
22 EXTRACTED XBRL INSTANCE DOCUMENT zk2330149_htm.xml XML 110804
Mailing Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002
Business Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002 972-77-331-0156
Chemomab Therapeutics Ltd. (Filer) CIK: 0001534248 (see all company filings)

IRS No.: 813676773 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-38807 | Film No.: 231166423
SIC: 2834 Pharmaceutical Preparations